219 related articles for article (PubMed ID: 2943705)
21. The effect of prolonged high dose misonidazole on tumor response to radiation.
McNally NJ; de Ronde J; Hinchliffe M
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1281-5. PubMed ID: 6469751
[TBL] [Abstract][Full Text] [Related]
22. Combinations of CCNU, MISO, and fractionated radiotherapy.
Siemann DW; Alliet KL
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1379-82. PubMed ID: 3759559
[TBL] [Abstract][Full Text] [Related]
23. Broad-shouldered survival curves of a human melanoma xenograft. Implications for radiation therapy in the absence and presence of misonidazole.
Rofstad EK; Brustad T
Acta Radiol Oncol; 1981; 20(4):261-5. PubMed ID: 6277155
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials of radiosensitizers: what should we expect?
Brown JM
Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
[TBL] [Abstract][Full Text] [Related]
25. [Recent advances in hypoxic cell radiosensitizer].
Ono K; Takahashi M; Nishidai T; Shibamoto Y; Abe M
Gan No Rinsho; 1983 Oct; 29(13):1608-12. PubMed ID: 6230470
[TBL] [Abstract][Full Text] [Related]
26. Sensitizers and protectors in clinical oncology.
Phillips TL
Semin Oncol; 1981 Mar; 8(1):65-82. PubMed ID: 6264627
[No Abstract] [Full Text] [Related]
27. Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.
Hirst DG; Hazlehurst JL; Brown JM
Br J Cancer; 1984 Jan; 49(1):33-42. PubMed ID: 6229264
[TBL] [Abstract][Full Text] [Related]
28. Clinical perspectives for the use of new hypoxic cell sensitizers.
Brown JM
Int J Radiat Oncol Biol Phys; 1982 Sep; 8(9):1491-7. PubMed ID: 6216229
[No Abstract] [Full Text] [Related]
29. Review: total doses in fractionated radiotherapy--implications of new radiobiological data.
Fowler JF
Int J Radiat Biol Relat Stud Phys Chem Med; 1984 Aug; 46(2):103-20. PubMed ID: 6381354
[TBL] [Abstract][Full Text] [Related]
30. Experimental intra-arterial administration of SR-2508 in the rabbit V2 carcinoma model.
Coldwell DM; Huff J; Marcellus H; Coldwell SG
Br J Radiol; 1989 Mar; 62(735):234-6. PubMed ID: 2522804
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
Hinchliffe M; McNally NJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
[TBL] [Abstract][Full Text] [Related]
32. Reduced fractionation and the potential of hypoxic cell sensitizers in irradiation of malignant epithelial tumors.
Cox JD; Byhardt RW; Komaki R; Greenberg M
Int J Radiat Oncol Biol Phys; 1980 Jan; 6(1):37-40. PubMed ID: 6245044
[No Abstract] [Full Text] [Related]
33. A comparison of tumor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole radiosensitizers in mice.
Minchinton AI; Stratford MR
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1117-20. PubMed ID: 2943710
[TBL] [Abstract][Full Text] [Related]
34. Dose-response relationships for human tumors: implications for clinical trials of dose modifying agents.
Williams MV; Denekamp J; Fowler JF
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1703-7. PubMed ID: 6237084
[TBL] [Abstract][Full Text] [Related]
35. Sensitization of mouse tumours using fractionated X-irradiation.
Denekamp J; Stewart FA
Br J Cancer Suppl; 1978 Jun; 3():259-63. PubMed ID: 277243
[TBL] [Abstract][Full Text] [Related]
36. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
Murayama C; Suzuki A; Sato C; Tanabe Y; Miyata Y; Shoji T; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1992; 22(3):557-60. PubMed ID: 1531214
[TBL] [Abstract][Full Text] [Related]
37. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
Siemann DW; Morrissey S; Wolf K
Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
[TBL] [Abstract][Full Text] [Related]
38. [Radiosensitizer: hypoxic cell radiosensitizer].
Mori T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001
[TBL] [Abstract][Full Text] [Related]
39. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
Van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1649-55. PubMed ID: 7153077
[TBL] [Abstract][Full Text] [Related]
40. Testing of new hypoxic cell sensitizers in vivo.
Stone HB; Sinesi MS
Radiat Res; 1982 Jul; 91(1):186-98. PubMed ID: 6212963
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
